Openly accessible

Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

McCaffrey, Nikki, Asser, T, Fazekas, B, Muircroft, W, Agar, M, Clark, K, Eckermann, S, Lee, J, Joshi, R, Allcroft, P, Sheehan, C and Currow, DC 2020, Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide, BMC Cancer, vol. 20, no. 1, pp. 1-9, doi: 10.1186/s12885-020-07549-y.

Attached Files
Name Description MIMEType Size Downloads
mccaffrey-health-relatedquality-2020.pdf Published version application/pdf 871.89KB 30

Title Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide
Author(s) McCaffrey, NikkiORCID iD for McCaffrey, Nikki orcid.org/0000-0003-3684-3723
Asser, T
Fazekas, B
Muircroft, W
Agar, M
Clark, K
Eckermann, S
Lee, J
Joshi, R
Allcroft, P
Sheehan, C
Currow, DC
Journal name BMC Cancer
Volume number 20
Issue number 1
Article ID 1050
Start page 1
End page 9
Total pages 9
Publisher BMC
Place of publication London, Eng.
Publication date 2020-10-31
ISSN 1471-2407
1471-2407
Keyword(s) Intestinal obstruction
Neoplasms
Palliative care
Patient-reported outcome measures
Randomised controlled trials
Terminal care
Science & Technology
Life Sciences & Biomedicine
Oncology
EORTC QLQ-C15-PAL
CANCER-PATIENTS
QUESTIONNAIRE
MANAGEMENT
EFFICACY
SAFETY
Summary Background: This analysis aims to evaluate health-related quality of life (HrQoL) (primary outcome for this analysis), nausea and vomiting, and pain in patients with inoperable malignant bowel obstruction (IMBO) due to cancer or its treatments randomised to standardised therapies plus octreotide or placebo over a maximum of 72 h in a double-blind clinical trial. Methods: Adults with IMBO and vomiting recruited through 12 services spanning inpatient, consultative and community settings in Australia were randomised to subcutaneous octreotide infusion or saline. HrQoL was measured at baseline and treatment cessation (EORTC QLQ-C15-PAL). Mean within-group paired differences between baseline and post-treatment scores were analysed using Wilcoxon Signed Rank test and between group differences estimated using linear mixed models, adjusted for baseline score, sex, age, time, and study arm. Results: One hundred six of the 112 randomised participants were included in the analysis (n = 52 octreotide, n = 54 placebo); 6 participants were excluded due to major protocol violations. Mean baseline HrQoL scores were low (octreotide 22.1, 95% CI 14.3, 29.9; placebo 31.5, 95% CI 22.3, 40.7). There was no statistically significant within-group improvement in the mean HrQoL scores in the octreotide (p = 0.21) or placebo groups (p = 0.78), although both groups reported reductions in mean nausea and vomiting (octreotide p < 0.01; placebo p = 0.02) and pain scores (octreotide p < 0.01; placebo p = 0.03). Although no statistically significant difference in changes in HrQoL scores between octreotide and placebo were seen, an adequately powered study is required to fully assess any differences in HrQoL scores. Conclusion: The HrQoL of patients with IMBO and vomiting is poor. Further research to formally evaluate the effects of standard therapies for IMBO is therefore warranted.
Language eng
DOI 10.1186/s12885-020-07549-y
Indigenous content off
Field of Research 1112 Oncology and Carcinogenesis
1117 Public Health and Health Services
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2020, The Authors
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30145241

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 61 Abstract Views, 32 File Downloads  -  Detailed Statistics
Created: Thu, 26 Nov 2020, 06:20:41 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.